COMMON BRAND NAME(S): Zyvox
GENERIC NAME(S): LINEZOLID
Description: Linezolid is a bacteriostatic oxazolidinone against gram positive bacteria which acts by inhibiting ribosomal protein synthesis.
Pharmacokinetics:
Absorption: Rapidly and extensively absorbed after oral admin. Absolute bioavailability: Approx 100%. Time to peak plasma concentration: 1-2 hr but reduced when administered w/ high-fat meal.
Distribution: Readily distributed into well-perfused tissues; lungs, fats, bone, skin blister fluids, muscle and into the CSF. Volume of distribution: 40-50 L. Plasma protein binding: Approx 31%.
Metabolism: Undergoes hepatic metabolism via oxidation to its 2 inactive metabolites (hydroxyethyl glycine and the aminoethoxyacetic acid metabolite).
Excretion: Via urine (approx 30% as parent drug and approx 50% as metabolites); faeces (approx 9% as metabolites). Elimination half-life: Approx 5-7 hr.